CD8A and lung carcinoma: We also investigated the involvement of a ColI receptor, Lair1, in CD8+ T cell dysfunction, given a recent report that Lair1 negatively regulates CD8+ T cell activity and may promote immunotherapy resistance in lung cancer (56).